A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

Men with rheumatoid arthritis have increased odds for heart failure vs women, particularly those with coronary heart disease. Men with rheumatoid arthritis (RA) have higher odds of developing heart ...

Cancer doctors across the US are running short of essential generic chemotherapy drugs, sparking fear of widespread rationing.

Intravenous lidocaine infusions for chronic pain are associated with a low incidence of serious adverse events, according to recent study results.

Adults who received the updated mRNA-1273 COVID-19 vaccine experienced a lower risk for hospitalization compared with NVX-CoV2705 recipients.

The FDA has approved Tryngolza (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (TG ≥500mg/dL).

Eosinophilic AE-COPD is associated with a lower risk for major adverse cardiovascular events (MACE) compared with noneosinophilic AE-COPD.

Evolocumab therapy reduces the risk for major cardiovascular events in stable patients with prior percutaneous coronary intervention.

Digoxin therapy may reduce the risk for new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease.

Despite an increased risk for cardiovascular disease, women with resolved pregnancy-only hypertension lack adequate preventive health care.

Only 49% of U.S. adults report being “cost secure,” meaning they can pay for the medical visits and treatments they need.

Both non-HDL-C and apolipoprotein B levels independently predict ASCVD risk in patients not receiving statins.